As drug costs continue to increase at an unsustainable rate, some hospitals are finding new solutions.
Use of pharmacogenomic testing enables physicians to ensure that the safest, most effective medications are prescribed to every patient, reducing trial and error prescribing and improving treatment outcomes.
This article explores Inova Health’s initiatives to make pharmacogenomics the standard of care, and how they integrated genomic decision support within the health system’s EHR.
Don Rule discusses how emerging tools could become as important to precision medicine as HTML is to the web.
Reporting and benchmarking are critical components in managing any pathology practice or clinical laboratory.
Precision medicine initiative at Holston Medical Group brings pharmacogenomics to the point of care.
RWJ University Hospital transformed its lab by implementing an analytics-driven outreach program.
When the CMS’ new 14-day rule took effect Jan. 1, conditions for laboratories doing outpatient reference testing might have changed for the better. But for labs navigating the new billing regulations, some forecasters are predicting confused seas ahead.
The government’s new clinical lab fee schedule will accelerate consolidation, competition, and cost-cutting.
Anatomic pathology systems providers need to be creative in helping their clients get the solutions they need to be scalable, competitive, and profitable.
Throughout 2018, we will see continued awareness and adoption of precision medicine both within the medical community and the population at large.
Pediatric pharmacogenomics is beginning to be used in pediatric hospitals to detect impaired or heightened drug responses, and may be coming to community pharmacies.
CVS Health's plans to create "community-based health hubs" following its acquisition of Aetna has the potential to push more basic lab services away from traditional lab providers
Using automated technology or outsourcing services dedicated for labs helps ensure the lab's high-volume claims get reimbursed.
CMS issued clinical lab fee schedule final prices slated to go into effect in 2018, even though a significant portion of the lab industry had urged the government payor to delay doing so.
Proposed 2018 Medicare payment rates for clinical diagnostic laboratory test have drawn concern and anger from labs and other industry stakeholders.
For research and clinical trials to succeed, it requires clearing some big hurdles – notably technology, financing and human factors.
A large-scale study strengthens the case that preemptive genotyping can provide actionable information to help clinicians make better treatment decisions
Lagging in precision medicine is an information system infrastructure that will provide the capability to store, access, and flag pharmacogenomics test results over our lifetimes, anywhere, any time.
Under the Protecting Access to Medicare Act of 2014, Medicare rates for laboratory tests will be recalculated to reflect market-based pricing. But are labs going to get a market-based price, or is CMS gaming the system to ensure there will be a cut to the fee schedule?
For hospital and health system labs, PAMA will substantially reduce Medicare payments for the highest volume diagnostic laboratory tests, a move that will have a significant impact on laboratory margins.
With outreach lab services becoming more and more critical to healthcare delivery models as testing availability increases, and with impending Medicare payment reform for laboratories in 2018, this is an optimal time to evaluate your RCM system's ability to help you sustain the challenges and opportunities ahead.
To optimize the implementation and potential benefits of a pharmacogenomic testing program, consideration should be given to choosing the right test menu, educating healthcare providers and patients, and seamlessly integrating pharmacogenomic data and clinical decision support systems into existing processes and systems.
Telehealth is fundamentally changing how healthcare leaders handle care delivery. In the ever-changing digital age, it’s important to stay current on telehealth to provide a higher level of care to patients and work toward improved interoperability within the healthcare system.
Integrated diagnostic and genomic reporting has significant potential to inform precision-based treatment and support collaborative, patient-centered care.
Older adults are at increased risk of adverse drug events, but would medication treatments that are tailored to each person’s genetic makeup help reduce dangerous side-effects and interactions in long-term care?
New API queries Knowledge-as-a-Service platform for drug-drug-gene intelligence to improve the prescription ordering process, alert clinicians to potential adverse drug events, and suggest medication alternatives.
In an uncertain reimbursement climate, some device manufacturers are considering new ways of billing to ensure revenue and profitability.
Sanford is expanding its genomics program — called Imagenetics — throughout the organization’s Epic electronic health records system, integrating genetics and genomic information into primary care for adults.
CMS has issued its final rule requiring laboratories providing clinical diagnostic tests to report rates paid by private payers.
By leveraging technology to help capture, interpret, and share PGx data, clinicians can make better decisions about care delivery.
A leading vendor of clinical decision support and precision medicine technology is working with First Databank on a new gene-based drug-drug interaction capability.
Inova Translational Medicine Institute has selected Translational Software as the data interpretation partner for MediMap, a new pharmacogenetics test for newborns that is now being offered at Inova Women's Hospital.
Health systems, social workers and advocacy groups are using connected care platforms to collaborate, giving front-line clinicians expert help in diagnosing children's cases.
The clinical laboratory community recognizes the need to provide payors and policymakers with a clear understanding of the value of diagnostic testing.
Laboratories continue to face numerous and unrelenting challenges driven by government and regulatory forces that leave many wondering how or if to move forward.
Engaging employees in wellness programs is challenging at the best of times, but for employers in industries where the majority of workers are not in an office setting, it can be even more difficult.
Social programs that support all areas of well-being are playing a key role in inspiring employees and increasing their ability to lead healthier lives.
Efforts to align pathology and radiology are picking up steam. As payment shifts to so-called value-based care and as medical record systems may challenge successful test interpretation, many experts seek a clear integration of these two specialties.
Revenue cycle management vendors share how they are helping their clients.
Congress has set laboratory medicine on a new course with a law that dramatically shifts how labs will be paid, upending a decades-old system of fee-for-service payment on the clinical laboratory fee schedule.
The addiction industry has caught on to the technological trend, with recovery apps continuing to gain momentum as a post-treatment tool.
As both regulators and molecular diagnostic testing companies implement a new reimbursement law, many stakeholders see opportunities for change.
Leaders at Memorial Hermann's Prevention and Recovery Center incorporate peer support tools to help their patients sustain recovery.
New digital tools and big data are combining to help improve health, wellness, and chronic disease.
Scheduled to be fully implemented in 2017, new legislation includes a number of key improvements and solutions to longstanding flaws in the current payment system for diagnostic tests.